Boehringer Ingelheim recently announced positive results regarding the safety, tolerability and efficacy of FDA-approved OFEV® (nintedanib*) in patients with idiopathic pulmonary fibrosis (IPF). The results were recently presented during the 2015 International Conference of the American Thoracic Society (ATS), which took place in Denver, and reveal continued long-term effectiveness in…
The Hastings Foundation has announced that it is going to grant $7.5 million in support to the University of South California (USC) for the creation of the Hastings Center for Pulmonary Research (HCPR) at Keck Medicine of USC. The grant will be spread across five years with the main purpose on improving research…
The Pulmonary Fibrosis Foundation (PFF) recently expressed its sadness over the loss of PFF Ambassador Diane Reichert, who has passed away. Diane received a diagnosis of idiopathic pulmonary fibrosis (IPF) in 2013, after which she became an Ambassador for the Foundation to help assist and raise awareness about her own disease. According to…
Boehringer Ingelheim Pharmaceuticals, Inc. recently announced in a press release that the company will present 29 abstracts on respiratory disorders at the 2015 American Thoracic Society (ATS) International Conference in Denver, May 15-20. The company will present the latest data on their investigational drug portfolio for disorders like chronic…
Hard at work in the laboratory of Dr. Christine Kim Garcia, Associate Professor of Internal Medicine at UT Southwestern Medical Center, is a group of researchers studying familial pulmonary fibrosis. The disease is characterized by fatal lung scarring and is now associated with mutations in two genes: PARN and RTEL1.
The Pulmonary Fibrosis Foundation (PFF) recently announced that registration for PFF Summit 2015: From Bench to Bedside is now open. This is an international conference focused on pulmonary fibrosis (PF), a deadly disease that results from lung scarring. The Summit will address medical education for healthcare professionals, conduct sessions dedicated to those that live with…
A team led by researchers at School of Pharmacy, Hampton University in Virginia recently discovered new key players in pulmonary fibrosis development and related angiogenesis. The study was published in the Journal of Cellular Biochemistry and is entitled “Nitric Oxide Mediates Bleomycin-Induced Angiogenesis and…
iBio, Inc, a leading pharmaceutical company using plant-based technology for developing and manufacturing biological products, has announced that it is now collaborating with Caliber Biotherapeutics LLC, which will be responsible for scaling-up and producing the necessary equipment for clinical development of iBio, Inc.’s lead anti-fibrosis product, IBIO-CFB03.
Molecular diagnostics company Veracyte, Inc., which is developing a genomic test to help improve diagnosis of Idiopathic Pulmonary Fibrosis (IPF) has announced the establishment of a definitive agreement for the trade of common stocks, worth $40 million, in a private placement. Investors acquired 4,907,975 shares of common stock at a purchase price of…
Researchers at Stanford University School of Medicine have come up with what appears to be one of the major keys in deciphering the mysteries of scarring. Their findings also included a molecule that could possibly reduce scarring and induce wound healing at the same time. Possibilities of this molecule being effective in…
Get regular updates to your inbox.
